FINWIRES · TerminalLIVE
FINWIRES

HKG:1951

3 stories mentioning HKG:1951Updated 21d ago

Every FINWIRES story that references HKG:1951, newest first.

Asia

Jinxin Fertility Forecasts Return to Profit in H1

Jinxin Fertility (HKG:1951) expects to post a profit of at least 90 million yuan for the first half, compared with a net loss of 1.04 billion yuan a year earlier, according to a Tuesday Hong Kong bourse filing.The in-vitro fertilization company attributed the growth in earnings to the continued recovery of its U.S. business, expansion of personalized services that increased VIP client penetration, and higher demand for assisted reproductive services in China.The turnaround to net profit primarily reflected the absence of significant impairment losses and other one-off items recognized in the year-earlier period.

HKG:1951
Asia

Jinxin Fertility Group Considers Launch of Asset-backed Security

Jinxin Fertility Group (HKG:1951) is considering launching an asset-backed securities program based on the underlying assets of its subsidiary Shenzhen Hengyu Lianxiang Investment Development, according to a Monday filing with the Hong Kong bourse.Hengyu Lianxiang Investment owns property in Shenzhen, which is currently used by the group's Shenzhen Zhongshan Hospital.The asset-backed security will be traded on the Shanghai Stock Exchange, the firm said.

HKG:1951
Asia

Jinxin Fertility Swings to Loss in 2025

Jinxin Fertility Group (HKG:1951) posted a loss attributable to owners of 976.1 million yuan for 2025, compared with a profit of 283.1 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.Shares of the in-vitro fertilization company fell over 1% in Friday afternoon trade.Loss per share came in at 0.36 yuan, compared with earnings per share of 0.10 yuan in 2024.Revenue fell 5.8% to 2.65 billion yuan from 2.81 billion yuan a year earlier.The board recommended a final dividend of HK$0.0418 per share.

HKG:1951

Track with the FINWIRES app suite